| BACKGROUND AND RATIONALE
Catheter-related arterial thrombosis (CAT) is increasingly recognized in children requiring monitoring in intensive care units or during surgery, and in children with congenital heart disease undergoing cardiac catheterization. CAT can cause serious acute signs and symptoms but also long-term complications such as leg length difference, claudication, and loss of arterial access for future diagnostic and therapeutic interventions. [1] [2] [3] However, there remains a paucity of data from well-designed studies on the incidence, risk factors, optimal diagnosis and treatment modalities, outcomes, and prognostic factors of pediatric CAT.
In order to advance knowledge on CAT in children, the Pediatric • The cumulative incidence of CAT among patients with indwelling arterial catheters (IC-CAT) was 24%, and that among for CC-CAT was 11%. However, incidence rates varied widely among studies depending on whether CAT was diagnosed based on surveillance imaging (including both symptomatic and asymptomatic CAT) or only in the presence of clinical signs or symptoms (symptomatic CAT).
• Prematurity (70%), respiratory distress syndrome (56%), asphyxia (35%), infection (32%), and cardiac disease (33%) were commonly identified factors/co-morbidities associated with IC-CAT. Risk factors for CC-CAT included younger age and body weight less than 10 kg.
• While CAT was frequently diagnosed by Doppler ultrasound, and less commonly by conventional angiography, studies comparing diagnostic performance among these and other imaging modalities are lacking.
• Antithrombotic treatment approaches varied widely between no antithrombotic therapy, the use of anticoagulant and/or antiplatelet therapy, and acute thrombolysis or thrombectomy. Use of thrombolysis (71%) or thrombectomy (31%) was highly prevalent among published studies, also potentially reflecting some reporting bias.
• With regard to outcomes, studies have mainly focused on acute mortality (3% among prospective studies, including mortality attributed to underlying disease) and on thrombus resolution; data on long-term outcomes and predictors of outcome (by which to optimally design future interventional trials) were sparse, even among prospective studies.
| METHODS
The 
| RECOMMENDATIONS
1. Future studies should better distinguish patients with IC-CAT and patients with CC-CAT, in order to achieve greater standardization in disease/subpopulation definitions. This will limit heterogeneity across studies, permitting more robust meta-analyses in the future. Table 1 .
| DISCUSSION
The present recommendations represent an effort to provide evidence-based guidelines for CAT in children as an emerging complication of pediatric tertiary care associated with significant morbidity and mortality. Three major key points from these recommendations warrant emphasis and discussion.
CAT mostly affects neonates and very young infants with severe medical conditions-a very particular vulnerable population. Trial designs and standardization of definitions in CAT will have to address the specific features and needs of this very young and often medically complex population. In particular, trials assessing optimal intensity, duration, and modality of antithrombotic therapy and optimal prevention strategies may warrant adaptation of primary and secondary outcome measures.
The recommended future research strategy will investigate two type of CAT, involving two different subpopulations. While IC-CAT occurs in neonates and young infants with several underlying diseases treated in intensive care units, CC-CAT will involve neonates and young infants undergoing cardiac catheterization for congenital heart disease. It is anticipated that recommended studies may warrant inclusion of different/additional objectives.
In specific regard to IC-CAT, additional partnership with the ISTH should be sought between pediatric intensivists, especially neonatology societies. For CC-CAT, partnership with the ISTH should be sought from pediatric cardiology and cardiothoracic surgery societies.
The recruitment of very young children in interventional trials is more challenging than for adults or older children because of the even greater perceived vulnerability of infants, and hence an understandable • CRNM bleeding: -overt bleed requiring blood product transfusion, not directly attributable to the patient's underlying condition -bleeding requiring medical or surgical intervention to restore hemostasis, other than in operating rooms -Other bleeding for which medical attention has been sought (e.g., emergency department, urgent care, or non-routine outpatient clinic visit) • Minor bleeding: -any overt macroscopic evidence of bleeding not fulfilling above criteria for major or clinical relevant bleeding CAT, catheter-related arterial thrombosis; CRNM, clinically relevant, non-major; Hgb, hemoglobin; QoL, quality of life.
TA B L E 1 Definitions of primary and secondary outcome measures in pediatric CAT
reticence of parents and clinicians to enroll infants on trials that are deemed to pose more than minimal risk. Collaborative multinational groups and/or pediatric clinical trials networks that pool quality data and resources are therefore an essential strategy to overcome the problem of underpowered trials due to low accrual in young children.
In addition, a prioritization strategy of recommended studies starting from rigorously designed and executed multicenter pediatric cohort studies that deeply characterize pediatric CAT (patient demographics and comorbidities, diagnostic features of thrombosis, treatments and durations administered, short-and long-term outcomes, and prognostic factors) will inform the design and conduct of risk-stratified randomized trials on treatment and prophylaxis of CAT.
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In conclusion, this article provides consensus recommendations for future research in pediatric CAT. These recommendations will need to be updated as evidence accrues and interdisciplinary collaborations ensue.
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